Russell Investments Group’s Day One Biopharmaceuticals DAWN Stock Holding History

Russell Investments Group’s Portfolio DAWN Stock Details DAWN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	$239K	Sell	11,134 -131,945	-92%	-$1.86M	﹤0.01%	2794
2025 Q4	$1.33M	Sell	143,079 -7,270	-5%	-$60.7K	﹤0.01%	2074
2025 Q3	$1.06M	Buy	150,349 +6,896	+5%	+$47.4K	﹤0.01%	2185
2025 Q2	$932K	Buy	143,453 +127,113	+778%	+$874K	﹤0.01%	2094
2025 Q1	$130K	Buy	16,340 +16,335	+326,700%	+$176K	﹤0.01%	2700
2024 Q4	$63	Sell	5 -26	-84%	-$362	﹤0.01%	3682
2024 Q3	$432	Sell	31 -1,720	-98%	-$24.5K	﹤0.01%	3584
2024 Q2	$24.1K	Buy	+1,751	New	+$25.6K	﹤0.01%	2907
2023 Q3	–	Sell	-3,530	Closed	-$42.1K	–	3550
2023 Q2	$42.1K	Sell	3,530 -1,600	-31%	-$20.9K	﹤0.01%	2747
2023 Q1	$68.6K	Buy	+5,130	New	+$100K	﹤0.01%	2661

Other funds holding DAWN

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

GCL

Glazer Capital LLC New York $4.71B AUM 81.93% 1-Year Est. Return

Fidelity International Hamilton, Bermuda $129B AUM 30.83% 1-Year Est. Return

Kryger Capital London, United Kingdom $1.41B AUM 86.31% 1-Year Est. Return

Deerfield Management New York $8.48B AUM 99.04% 1-Year Est. Return

VCM

Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Balyasny Asset Management Chicago, Illinois $77.1B AUM 42.89% 1-Year Est. Return

AQR Arbitrage Greenwich, Connecticut $6.09B AUM 27.01% 1-Year Est. Return

Russell Investments Group's DAWN Position: Q1 2026 in Review

Russell Investments Group reduced its Day One Biopharmaceuticals (DAWN) stake by 92% in Q1 2026, selling an estimated $1.86M and leaving 11,134 shares worth $239K. The position accounts for ﹤0.01% of the portfolio, ranked #2794.

Russell Investments Group first reported a position in DAWN in Q1 2023 and has held it in 10 quarters since. The position peaked at $1.33M in Q4 2025. 206 funds tracked by Wall St. Rank hold DAWN as of Q1 2026.

Russell Investments Group held 11,134 shares of Day One Biopharmaceuticals worth $239K as of Q1 2026.
Russell Investments Group sold 131,945 Day One Biopharmaceuticals shares in Q1 2026, an estimated $1.86M.
Day One Biopharmaceuticals made up ﹤0.01% of Russell Investments Group's portfolio in Q1 2026, its #2794 holding.
Russell Investments Group first reported a position in Day One Biopharmaceuticals in Q1 2023 and has held it in 10 quarters since.
Russell Investments Group's Day One Biopharmaceuticals position peaked at $1.33M in Q4 2025.
206 funds tracked by Wall St. Rank held Day One Biopharmaceuticals as of Q1 2026.

Based on Russell Investments Group's 13F filing for Q1 2026, filed 8 May 2026.